poisar

Stock

Propanc Biopharma, Inc. PPCB

$1.39-2.46%

Overview

PPCB market data

Price History

PPCB price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$371.22
Diluted earnings per share over the trailing twelve months.
Beta
3.15
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.30 – $270.25
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.7 · P/B 3.47.

Company news

10 captured
Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell FactoriesBenzinga · Jul 21, 2026, 12:33 PM
8-K filing — Propanc Biopharma, Inc. (PPCB)SEC EDGAR · Jul 14, 2026, 8:01 PM
Propanc Biopharma Signs MoU With Avance Clinical To Support Delivery Of The Company's Phase 1B Trial For Lead Candidate PRP For Advanced Solid TumorsBenzinga · Jul 7, 2026, 12:40 PM
Propanc Biopharma Initiates First Tranche Of $500K Stock Buyback PlanBenzinga · Jul 2, 2026, 12:35 PM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga · Jun 11, 2026, 3:44 PM
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseBenzinga · Jun 11, 2026, 1:55 PM
Propanc Biopharma shares are trading higher after the company announced a $5 million share repurchase program.Benzinga · Jun 11, 2026, 12:40 PM
Propanc Biopharma Announces $5M Common Stock Buyback PlanBenzinga · Jun 11, 2026, 12:34 PM
Propanc Biopharma To File CTA In Australia For Phase 1b Study In 30–40 Advanced Cancer Patients; Plans Two Phase 2 Studies In Pancreatic And Ovarian Cancers With 60 Patients EachBenzinga · May 20, 2026, 1:00 PM
Propanc Biopharma Engages Manufacturer For Its Lead Asset PRP Ahead Of The Upcoming Phase 1b, First-in-Human Study In 30-40 Advanced Cancer Patients Suffering From Solid TumorsBenzinga · May 19, 2026, 12:55 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock